Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma

Bibliography

• Fitzgerald JM, Boulet LP, McIvor RA, et al. Asthma control in Canada remains suboptimal: the reality of asthma control (TRAC study). Can Respir J 2006;13:253-9
   PubMedGoogle Scholar
• Boulet LP. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest 1998;113:587-92
   PubMed Web of Science ®Google Scholar
• Jemal A, Ward E, Hao Y, et al. Trends in the leading causes of death in the United States, 1970 – 2002. JAMA 2005;294:1255-9
   PubMed Web of Science ®Google Scholar
• Turato G, Zuin R, Miniati M, et al. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med 2002;166:105-10
   PubMed Web of Science ®Google Scholar
• Agusti A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should). Proc Am Thorac Soc 2007;4:522-5
   PubMedGoogle Scholar
• Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. New Engl J Med 2004;350:2645-53
   PubMed Web of Science ®Google Scholar
• O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease-2007 update. Can Respir J 2007;14(Suppl B):B5-32
   PubMed Web of Science ®Google Scholar
• Tattersfield AE, Harrison TW, Hubbard RB, et al. Safety of inhaled corticosteroids. Proc Am Thorac Soc 2004;1:171-5
   PubMedGoogle Scholar
• Torphy TJ. Phosphodiesterase isozymes. Molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998;157:351-70
   PubMed Web of Science ®Google Scholar
• Reid P. Roflumilast Altana Pharma. Current Opin Invest Drugs 2002;3:1165-70
   PubMedGoogle Scholar
• Boswell-Smith V, Cazola M, Page CP. Are phosphodiesterase 4 inhibitors just more theophylline? J Allergy Clin Immunol 2006;117:1237-43
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Theophylline for COPD. Thorax 2006;61:742-4
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Theophylline. New perspectives for an old drug. Am J Respir Crit Care Med 2003;167:813-8
   PubMed Web of Science ®Google Scholar
• Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999;160:1001-8
   PubMed Web of Science ®Google Scholar
• Spina D. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs 2003;63:2575-94
   PubMed Web of Science ®Google Scholar
• Card GL, England BP, Suzuki Y, et al. Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure 2004;12:2233-47
   PubMed Web of Science ®Google Scholar
• Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005;365:167-75
   PubMed Web of Science ®Google Scholar
• Hauns B, Hermann R, Huennemeyer A, et al. Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects. J Clin Pharmacol 2006;46:1146-53
   PubMed Web of Science ®Google Scholar
• Nassr N, Lahu G, von Richter O, et al. Magnesium hydroxide/aluminium hydroxide-containing antacid does not affect the pharmacokinetics of the targeted phosphodiesterase 4 inhibitor roflumilast. J Clin Pharmacol 2007;47:660-6
   PubMed Web of Science ®Google Scholar
• Hermann R, Nassr N, Lahu G, et al. Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis. Clin Pharmacokinet 2007;46:403-16
   PubMed Web of Science ®Google Scholar
• Herrmann R, Siegmund W, Giessmann T, et al. The oral, once daily phosphodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic interactions with inhaled budesonide. J Clin Pharmacol 2007;47:1005-13
   PubMed Web of Science ®Google Scholar
• Bethke TD, Giessmann T, Westphal K, et al. Roflumilast, once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacologic interactions with inhaled salbutamol when co-administered in healthy subjects. Int J Pharmacol Ther 2006;44:572-9
   Web of Science ®Google Scholar
• de May C, Hauns B, Reutter F, et al. Repeated-dose co-administration of roflumilast and formoterol does not alter the pharmacokinetics of either drug. Am J Respir Crit Care Med 2007;175:A113
   Google Scholar
• Nassr N, Lahu G, von Richter O, et al. Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects. Br J Clin Pharmacol 2007;63:365-70
   PubMed Web of Science ®Google Scholar
• von Richter O, Lahu G, Huennemeyer A, et al. Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide. Clin Pharmacokinet 2007;46:613-22
   PubMed Web of Science ®Google Scholar
• Lahu G, Huennemeyer A, Herzog R, et al. Effect of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide. Am J Respir Crit Care Med 2006;173:A850
   Google Scholar
• Lahu G, Huennemeyer A, Reutter F, et al. Pharmacokinetics of roflumilast and roflumilast N-oxide with concomitant ketoconazole. Am J Respir Crit Care Med 2006;173:A850
   Google Scholar
• Bundschuh DS, Eltze M, Barsig J, et al. In vivo efficacy in airway disease models of roflumilast, novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 2001;297:280-90
   PubMed Web of Science ®Google Scholar
• Wollin L, Bundschuh DS, Wohlsen A, et al. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors. Pulm Pharm Ther 2006;19:343-52
   PubMed Web of Science ®Google Scholar
• Wollin L, Marx D, Wohlsen A, et al. Roflumilast inhibition of pulmonary leukotriene production and bronchoconstriction in ovalbumin-sensitized and -challenged Guinea pigs. J Asthma 2005;42:873-8
   PubMed Web of Science ®Google Scholar
• Sanz M-J, Cortijo J, Taha MA, et al. Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability. Br J Pharmacol 2007;152:481-92
   PubMed Web of Science ®Google Scholar
• Jones NA, Boswell-Smith V, Lever R, Page CP. The effect of selective phosphodiesterase isozyme inhibition on neutrophil function in vitro. Pulm Pharmacol Ther 2005;18:93-101
   PubMed Web of Science ®Google Scholar
• Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001;297:267-79
   PubMed Web of Science ®Google Scholar
• Timmer W, Leclerc V, Birraux G, et al. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo. J Clin Pharmacol 2002;42:297-303
   PubMed Web of Science ®Google Scholar
• Sumi Y, Hamid Q. Airway remodeling in asthma. Allergol Int 2007;56:341-8
   PubMedGoogle Scholar
• Boero S, Silvestri M, Sabatini F, et al. Inhibition of lung fibroblast proinflammatory functions by roflumilast N-oxide. Am J Respir Crit Care Med 2006;173:A33
   Google Scholar
• Klar J, Sabatini F, Schatton E, et al. Roflumilast N-oxide reduces human fibroblast function. Eur Respir J 2007;30(Suppl 51):544S
   Google Scholar
• Burgess JK, Oliver BG, Poniris MH, et al. A phosphodiesterase 4 inhibitor inhibits matrix protein deposition in airways in vitro. J Allergy Clin Immunol 2006;118:649-57
   PubMed Web of Science ®Google Scholar
• Louw C, Williams Z, Venter L, et al. Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge. Respiration 2007;74:411-7
   PubMed Web of Science ®Google Scholar
• Kanniess F, Beler J, Beeh K-M, et al. Effects of roflumilast on exhaled NO, airway hyperresponsiveness, and inflammatory markers in patients with asthma. Eur Respir J 2006;28(Suppl 50):670S
   PubMedGoogle Scholar
• Gauvreau GM, Boulet LP, Cote J, et al. Effects of roflumilast on airway inflammation and function following allergen challenge in patients with allergic asthma. Am J Respir Crit Care Med 2007;175:A484
   Google Scholar
• van Schalkwyk E, Strydom K, Williams Z, et al. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J Allergy Clin Immunol 2005;116:292-8
   PubMed Web of Science ®Google Scholar
• Schmidt BMW, Kusma M, Feuring M, et al. The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis. J Allergy Clin Immunol 2001;108:530-6
   PubMed Web of Science ®Google Scholar
• Bateman ED, Izqueirdo JL, Harnest U, et al. Efficacy and safety of roflumilast in the treatment of persistent asthma. Ann Allergy Asthma Immunol 2006;96:679-86
   PubMed Web of Science ®Google Scholar
• Bousquet J, Aubier M, Sastre J, et al. Comparison of roflumilast, an oral, anti-inflammatory, with beclomethasone diproprionate in the treatment of persistent asthma. Allergy 2006;61:72-8
   PubMed Web of Science ®Google Scholar
• Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004;364:709-21
   PubMed Web of Science ®Google Scholar
• Martorana PA, Beume R, Lucattelli M, et al. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 2005;172:848-53
   PubMed Web of Science ®Google Scholar
• Fitzgerald MF, Spicer D, McAulay AE, et al. Roflumilast but not methylprednisolone inhibited cigarette smoke-induced pulmonary inflammation in guinea pigs. Eur Respir J 2006;28(Suppl 50):663S
   Google Scholar
• Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007;62:1081-7
   PubMed Web of Science ®Google Scholar
• Rabe K, Bateman ED, O'Donnell D, et al. Roflumilast–an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005;366:563-71
   PubMed Web of Science ®Google Scholar
• Calverley PMA, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:154-61
   PubMed Web of Science ®Google Scholar
• Rutten-van Molken MP, van Nooten FE, Lindemann M, et al. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease. Pharmacoeconomics 2007;25:695-711
   PubMed Web of Science ®Google Scholar
• Lipworth B. Phosphodiesterase type 4 inhibitors for asthma: a real breakthrough or just expensive theophylline? Ann Allergy Asthma Immunol 2006;96:640-1
   PubMed Web of Science ®Google Scholar
• Green RH, Brightling CE, Woltmann G, et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002;57:875-9
   PubMed Web of Science ®Google Scholar
• Shannon J, Ernst P, Yamauchi Y, et al. Differences in airway cytokine profile in severe asthma compared to moderate asthma. Chest 2008;133:420-6
   PubMed Web of Science ®Google Scholar
• Suissa S, McGhan R, Niewohner D, Make B. Inhaled corticosteroids in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4:535-42
   PubMedGoogle Scholar
• Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New Engl J Med 2007;356:775-89
   PubMed Web of Science ®Google Scholar
• Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease. Ann Intern Med 2007;146:545-55
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PMA, Seemungal TA, et al. The prevention of COPD exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26
   PubMed Web of Science ®Google Scholar
• Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007;176:162-6
   PubMed Web of Science ®Google Scholar
• The Helios study BY217/M2-128. 24 weeks treatment with roflumilast or placebo in COPD patients treated with tiotropium 18 μg daily. Available from: http://clinicaltrials.gov/ct2/show/NCT00424268?term%20=%20roflumilast+and+tiotropium&rank=1
   Google Scholar